Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Syros Pharmaceuticals (SYRS)

Syros Pharmaceuticals (SYRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates Zacks - Wed May 10, 2023

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 24.11% and 0.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

SYRS : 5.14 (+0.19%)
ARAV : 0.0401 (-13.39%)
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates Zacks - Tue May 9, 2023

Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 11.11% and 13.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

TNGX : 7.74 (+1.71%)
SYRS : 5.14 (+0.19%)
ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar? Zacks - Sun May 7, 2023

ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

IBRX : 8.93 (-2.40%)
SYRS : 5.14 (+0.19%)
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023 Business Wire - Wed May 3, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host...

SYRS : 5.14 (+0.19%)
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Tue May 2, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted...

SYRS : 5.14 (+0.19%)
Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates Zacks - Thu Mar 2, 2023

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

SYRS : 5.14 (+0.19%)
VRDN : 15.39 (-0.06%)
Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update Business Wire - Thu Mar 2, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for...

SYRS : 5.14 (+0.19%)
Syros to Participate in Upcoming Investor Conferences in March Business Wire - Tue Feb 28, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive...

SYRS : 5.14 (+0.19%)
Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023 Business Wire - Thu Feb 23, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host...

SYRS : 5.14 (+0.19%)
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Thu Feb 9, 2023

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted...

SYRS : 5.14 (+0.19%)

Barchart Exclusives

Will This EV Stock Burn Short Sellers Like Tesla Did With Its Q1 Earnings Report? Barchart - 25 minutes ago
Rivian will release its Q1 earnings after the bell this Tuesday, May 7. The setup for the EV startup looks good heading into the release, which could set the stage for a post-earnings rebound like we saw with Tesla. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot